AstraZeneca's Imfinzi regimen approved by MHRA to treat resectable lung cancer
09 Jul 2024
Preview
Source: PMLiVE
AstraZeneca (AZ) has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for its Imfinzi (durvalumab) regimen in a subset of adults with resectable non-small cell lung cancer (NSCLC).
The anti-PDL1 antibody is now approved in Great Britain for use alongside platinum-based chemotherapy as a neoadjuvant treatment before surgery and then as an adjuvant monotherapy after surgery.
Patients eligible for the regimen will have resectable NSCLC and no known epidermal growth factor receptor mutations, ALK rearrangements or aberrations.
The MHRA’s decision, which means that Imfinzi is now approved in Great Britain to treat both resectable and unresectable NSCLC, was supported by positive results from the late-stage AEGEAN trial.
Patients treated with the Imfinzi regimen achieved a 32% reduction in the risk of recurrence, progression or death compared to neoadjuvant chemotherapy alone.
The combination also demonstrated a pathologic complete response rate of 17.2% versus 4.3% for patients receiving neoadjuvant chemotherapy only.
Lung cancer accounts for 21% of all cancer deaths in the UK and NSCLC accounts for up to 85% of all lung cancer diagnoses.
David Harland, head of oncology medical affairs, AZ UK, said the latest approval “marks a major advancement and opens a new chapter in the treatment of resectable NSCLC”.
Hardland added that the company is now “committed to working with the National Institute for Health and Care Excellence and NHS England to ensure rapid access for patients”.
Sharing a similar sentiment, Dr John Conibear, clinical director of thoracic oncology at Barts Cancer CentreCancer Centre, said: “This decision by the MHRA recognises an important clinical improvement in outcomes for patients with resectable NSCLC, where new options are urgently needed for long-term survival.”
The approval comes just over one week after Imfinzi and AZ’s PARP inhibitor LynparzaPARP inhibitor Lynparza (olaparib) were recommended by the European Medicines Agency’s human medicines committee to treat certain endometrial cancer patients.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.